Population pharmacokinetics of pyrimethamine and sulfadoxine in children with congenital toxoplasmosis

AIMS: To develop a population pharmacokinetic model for pyrimethamine (PYR) and sulfadoxine (SDX) in children with congenital toxoplasmosis. METHODS: Children were treated with PYR (1.25 mg kg(−1)) and SDX (25 mg kg(−1)) (Fansidar®) plus folinic acid (Lederfoline® 5 mg). Plasma concentrations, avail...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Trenque, T, Simon, N, Villena, I, Chemla, C, Quereux, C, Leroux, B, Jaussaud, R, Rémy, G, Dupouy, D, Millart, H, Pinon, J-M, Urien, S
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Blackwell Science Inc 2004
Pynciau:
Pharmacokinetics
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC1884514/
https://ncbi.nlm.nih.gov/pubmed/15151519
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2125.2004.02077.x
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg